Skip to content

Hyperbaric Oxygen Therapy for Lung Transplantation

Hyperbaric Oxygen Therapy for Lung Transplantation-Associated Pseudomembranes and Central Airway Stenosis

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02363959
Enrollment
20
Registered
2015-02-16
Start date
2015-02-28
Completion date
2018-09-30
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Complications Post-Lung Transplantation, Airway Exudative Plaques, Central Airway Stenosis, Disorder Related to Lung Transplantation

Keywords

Hyperbaric Oxygen, Lung Transplantation, Central Airway Stenosis, Airway Exudative Plaques, Hyperbaric Oxygen Therapy, Post-Lung Transplantation, Airway Ischemia, Endobronchial Biopsy, Bronchoscopy

Brief summary

The objective of this study is to evaluate the effect of hyperbaric oxygen therapy (HBOT) on airway complications in post-lung transplant recipients with evidence of restricted levels of blood and oxygen in the airway tissue. Study subjects with extensive airway tissue damage in the early post-transplant period will be randomized to HBOT or usual care and followed clinically for 12 months following randomization. The investigators hypothesize that HBOT will decrease the number of airway complications in the treated subjects.

Detailed description

Hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician. The HBOT procedure used for this study will be identical to that used for clinical practice in the Duke University Health System Center for Hyperbaric Medicine and Environmental Physiology, including the oxygen that is used in the chamber. Patients will receive treatment through the regular clinical hyperbaric service. These are routine, not special, treatment sessions and they will receive them alongside other Duke University Medical Center patients being treated for other reasons. The medical grade oxygen used is a part of the Duke University Health System Center for Hyperbaric Medicine and Environmental Physiology hyperbaric chamber system. While the patients randomized to receive usual care will not undergo HBOT, both study groups will receive standard serial bronchoscopies for airway clearance and for the collection of bronchoalveolar lavage fluid for culture data, due to the high rate of infection in lung transplant patients. All subjects will undergo the standard surveillance bronchoscopies every 3 to 4 weeks (x3) for clearance of the exudate from the airway, as well as monitoring progression of the airway abnormalities. As participants in this study, an, endobronchial biopsy of the airway epithelium will be performed at the main carina to collect a sample of recipient epithelium as well as at the first subcarina for each donor lung. Three samples will be collected from each of the biopsy sites. These samples are small (1 to 2 mm) and are thought to have a minimal clinical risk of minor bleeding associated with the procedure. Biopsy will add roughly 3 minutes total to each procedure.

Interventions

DRUGHyperbaric Oxygen Therapy

2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.

PROCEDUREEndobronchial Biopsy of Airway Epithelium

During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Post-lung transplant patient * Extensive exudative plaques at 1 month bronchoscopy * No sign of airway improvement, or showing worsening of plaques at follow-up bronchoscopy 2-3 weeks after 1 month bronchoscopy.

Exclusion criteria

* Use of mechanical ventilation with fraction of inspired oxygen(FiO2) greater than 40% * Use of extracorporeal membrane oxygenation * Use of inhaled nitric oxide * Presence of pneumothorax * Pregnancy * Inability to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Number of Subjects Experiencing Acute Cellular Rejection as Determined by Transbronchial Lung Biopsy12 monthsPathologic specimens will be examined for the presence of acute cellular rejection.
Subjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy.12 monthsAirways with stenosis refractory to serial balloon dilation x 3, or at risk for acute obstruction due to stenosis were treated with airway stents.

Secondary

MeasureTime frameDescription
Number of Subjects Receiving Balloon Bronchoplasty for Management of Stenosis12 months
Number of Subjects With Development of Bronchitis Obliterans Syndrome12 months
Number of Subjects With Development of Clinically Significant Lung Infection12 monthsAs defined by initiation of antimicrobials to treat the suspected organism.
Number of Subjects With Development of Clinically Significant Airway Stenosis12 months

Other

MeasureTime frame
Bronchial Epithelial Gene Expression12 months

Countries

United States

Participant flow

Participants by arm

ArmCount
Hyperbaric Oxygen, Airway Biopsy
The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician. During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
10
No Hyperbaric Oxygen, Airway Biopsy
No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure. Endobronchial Biopsy of Airway Epithelium: During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
10
Total20

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyMedical instability10

Baseline characteristics

CharacteristicHyperbaric Oxygen, Airway BiopsyTotalNo Hyperbaric Oxygen, Airway Biopsy
Age, Continuous53.65 years
STANDARD_DEVIATION 14.8
52.86 years
STANDARD_DEVIATION 18.04
52.07 years
STANDARD_DEVIATION 18.76
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants19 Participants10 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
10 Participants20 Participants10 Participants
Region of Enrollment
United States
10 Participants20 Participants10 Participants
Sex: Female, Male
Female
4 Participants10 Participants6 Participants
Sex: Female, Male
Male
6 Participants10 Participants4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 101 / 10
other
Total, other adverse events
0 / 100 / 10
serious
Total, serious adverse events
1 / 100 / 10

Outcome results

Primary

Number of Subjects Experiencing Acute Cellular Rejection as Determined by Transbronchial Lung Biopsy

Pathologic specimens will be examined for the presence of acute cellular rejection.

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hyperbaric Oxygen, Airway BiopsyNumber of Subjects Experiencing Acute Cellular Rejection as Determined by Transbronchial Lung Biopsy4 Participants
No Hyperbaric Oxygen, Airway BiopsyNumber of Subjects Experiencing Acute Cellular Rejection as Determined by Transbronchial Lung Biopsy7 Participants
p-value: 0.39Fisher Exact
Primary

Subjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy.

Airways with stenosis refractory to serial balloon dilation x 3, or at risk for acute obstruction due to stenosis were treated with airway stents.

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hyperbaric Oxygen, Airway BiopsySubjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy.4 Participants
No Hyperbaric Oxygen, Airway BiopsySubjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy.4 Participants
p-value: 1Fisher Exact
Secondary

Number of Subjects Receiving Balloon Bronchoplasty for Management of Stenosis

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hyperbaric Oxygen, Airway BiopsyNumber of Subjects Receiving Balloon Bronchoplasty for Management of Stenosis5 Participants
No Hyperbaric Oxygen, Airway BiopsyNumber of Subjects Receiving Balloon Bronchoplasty for Management of Stenosis4 Participants
p-value: 1Fisher Exact
Secondary

Number of Subjects With Development of Bronchitis Obliterans Syndrome

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hyperbaric Oxygen, Airway BiopsyNumber of Subjects With Development of Bronchitis Obliterans Syndrome0 Participants
No Hyperbaric Oxygen, Airway BiopsyNumber of Subjects With Development of Bronchitis Obliterans Syndrome1 Participants
p-value: 1Fisher Exact
Secondary

Number of Subjects With Development of Clinically Significant Airway Stenosis

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hyperbaric Oxygen, Airway BiopsyNumber of Subjects With Development of Clinically Significant Airway Stenosis5 Participants
No Hyperbaric Oxygen, Airway BiopsyNumber of Subjects With Development of Clinically Significant Airway Stenosis4 Participants
p-value: 1Fisher Exact
Secondary

Number of Subjects With Development of Clinically Significant Lung Infection

As defined by initiation of antimicrobials to treat the suspected organism.

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hyperbaric Oxygen, Airway BiopsyNumber of Subjects With Development of Clinically Significant Lung Infection8 Participants
No Hyperbaric Oxygen, Airway BiopsyNumber of Subjects With Development of Clinically Significant Lung Infection7 Participants
p-value: 1Fisher Exact
Other Pre-specified

Bronchial Epithelial Gene Expression

Time frame: 12 months

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026